Screener
Harmony Biosciences Holdings, Inc. HRMY Business Segments — Net Income Loss
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Harmony Biosciences Holdings, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetIncomeLoss.
The source filing: Harmony Biosciences Holdings, Inc.’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 8:16 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001104659-26-056720
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Interest income | 5,757 | 5,044 |
| Income before income taxes | 39,687 | 57,177 |
| Income tax expense | (7,199) | (11,617) |
| Net income | $32,488 | $45,560 |
| Unrealized (loss) income on investments | (759) | 179 |
| Comprehensive income | $31,729 | $45,739 |
| EARNINGS PER SHARE: | ||
| Basic | $0.56 | $0.79 |
Item 1. Financial Statements
FAQ
- What is Harmony Biosciences Holdings, Inc.'s business segments — net income loss?
- Harmony Biosciences Holdings, Inc. (HRMY) reported business segments — net income loss of $32.49M in Q1 2026.
- How has Harmony Biosciences Holdings, Inc.'s business segments — net income loss changed year-over-year?
- Harmony Biosciences Holdings, Inc.'s business segments — net income loss decreased by 28.7% year-over-year, from $45.56M to $32.49M.
- What is the long-term trend for Harmony Biosciences Holdings, Inc.'s business segments — net income loss?
- Over 3 years (2022 to 2025), Harmony Biosciences Holdings, Inc.'s business segments — net income loss has grown at a -4.4% compound annual growth rate (CAGR), from $181.47M to $158.69M.
- What does business segments — net income loss mean?
- This metric measures the total profitability of the rare neurological diseases segment after accounting for all associated revenues and operating expenses. It serves as the primary indicator of the segment's financial health and its contribution to the overall corporate bottom line. A positive value indicates the segment is self-sustaining and profitable, while a negative value suggests the segment is currently a drain on corporate resources.
Ask your AI about Harmony Biosciences Holdings, Inc.'s business segments — net income loss.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude